NEET MDS Lessons
Pharmacology
Serotonin-norepinephrine reuptake inhibitors(SNRIs)
e.g. venlafaxine and duloxetine
- Inhibit the reuptake of both 5-HT and norepinephrine
- Has a more favourable adverse effect profile than TCAs
Norepinephrine reuptake inhibitor
e.g. bupropion, reboxetine
Monoamine receptor antagonists
e.g. mirtazapine, trazodone, mianserin
Metabolism
Hepatic Drug-Metabolizing Enzymes: most drug metabolism in the liverperformed by the hepatic microsomal enzyme system.
Therapeutic Consequences of Drug Metabolism
- Accelerated Renal Drug Excretion: The most important consequence of drug metabolism is the promotion of renal drug excretion. Metabolism makes it possible for the kidney to excrete many drugs that it otherwise could not.
- Drug Inactivation
- Increased Therapeutic Action: Metabolism may increase the effectiveness of some drugs.
- Activation of Prodrugs: A prodrug is a compound that is inactive when administered and made active by conversion in the body.
- Increased or Decreased Toxicity
Factors that influence rate of metabolism:
- Age: Hepatic maturation doesn't occur until about a year old.
- Induction of Drug-Metabolizing Enzymes: Some drugs can cause the rate of metabolism to increase, leading to the need for an increased dosage. May also influence the rate of metabolism for other drugs taken at the same time, leading to a need for increased dosages of those drugs as well.
- First-Pass Effect: Hepatic inactivation of certain oral drugs. Avoided by parentaral administration of drugs that undergo rapid hepatic metabolism.
- Nutritional Status
- Competition between Drugs
Needle selection
Nerve blocks:
Inferior alveolar- 25 G short (LLU technique)
PSA- 25 G short
Mental/Incisive- 25 G short
Palatal- 27/30 G short/ultrashort
Gow-Gates/Akinosi- 25 G long
Infraorbital- 25 G long
Field Block:
ASA 25/27 short
Infiltration:
Infiltration/SP 25/27 short
PDL/Intraosseous
PDL 27/30 short
Intraosseous 30 short/ultrashort
Fentanyl (Sublimaze)
- Related chemically to meperidine.
- Approximately 80 times more potent than morphine.
- Duration of action very short (t1/2 20 min).
- Used mainly following general anesthesia.
- Neurolept analgesia: Fentanyl & Droperidol (Innovar)
- fentanyl in analgesic (2-10 µg/kg), or anaesthetic (30-100 µg/kg) doses seldom causes significant decreases in blood pressure when given alone, even in patients with poor LV function
- hypotension following fentanyl is mostly due to bradycardia and can be prevented by the use of anticholinergics, sympathomimetics or agents such as pancuronium this is more likely to occur in patients with high pre-existing sympathetic tone
- hypertension is the commonest disturbance with high dose fentanyl anaesthesia, usually accompanying intubation, sternotomy, or aortic root dissection
Barbiturates
1. Long-acting. Phenobarbital is used to treat certain types of seizures (see section on antiepileptic drugs).
2. Intermediate-acting. Amobarbital, pentobarbital (occasionally used for sleep), secobarbital.
3. Short-acting. Hexobarbital, methohexital, thiopental—rarely used as IV anesthetics.
NSAIDs: Classification by Plasma Elimination Half Lives
Short Half Life (< 6 hours):
more rapid effect and clearance
• Aspirin (0.25-0.33 hrs),
• Diclofenac (1.1 ± 0.2 hrs)
• Ketoprofen (1.8± 0.4 hrs),
• Ibuprofen (2.1 ± 0.3 hrs)
• Indomethacin (4.6 ± 0.7 hrs)
Long Half Life (> 10 hours):
slower onset of effect and slower clearance
• Naproxen (14 ± 2 hrs)
• Sulindac (14 ± 8 hrs),
• Piroxicam (57 ± 22 hrs)
Nitrous Oxide (N2O)
MAC 100%, blood/gas solubility ratio 0.47
- An inorganic gas., low solubility in blood, but greater solubility than N2
- Inflammable, but does support combustion.
- Excreted primarily unchanged through the lungs.
- It provides amnesia and analgesia when administered alone.
- Does not produce muscular relaxation.
- Less depressant to both the cardiovascular system and respiratory system than most of the other inhalational anesthetics.
- Lack of potency and tendency to produce anoxia are its primary limitations.
- The major benefit of nitrous oxide is its ability to reduce the amount of the secondary anesthetic agent that is necessary to reach a specified level of anesthesia.